TL;DR – Summary of Case Study Published in JITC

On the heels of our recent? Cell Press ' Med paper presenting our ENLIGHT treatment matching platform, we are proud to share a case report in?the Journal for ImmunoTherapy of Cancer (JITC) about a young patient achieving complete remission from advanced cancer following ENLIGHT-matched therapy. https://bit.ly/3FpV01c

The patient's tumor, diagnosed as Fibrolamellar Carcinoma - a rare liver cancer - proved resistant to several lines of treatment and metastasized to other organs. No “actionable mutations” were identified in comprehensive molecular profiling of the tumor performed by? Tempus AI

Her physician - Prof. Raanan Berger of Sheba Medical Center - ordered ENLIGHT analysis of the raw data from? Tempus AI The ENLIGHT report highlighted both PD1 and CTLA4 as desirable targets of Immune Checkpoint Blockade (ICB).

The ENLIGHT results were surprising since the patient was strictly negative for 3 standard biomarkers of ICB: TMB, PDL1 by IHC, and MSI. Nevertheless, treatment with combination of nivolumab (PD1 blocker) and ipilimumab (CTLA4 blocker) was started and improvement was quick.

Within several months, no traces of the primary tumor or metastases were visible in PET-CT imaging, and the patient returned to normal life. Two and a half years later, the patient is still in complete remission.

This case demonstrates the power of deep genetic interaction-based analysis to highlight treatment options missed by standard biomarkers. Together with our collaborators from National Cancer Institute (NCI) , we are preparing to put this methodology to the test in large prospective clinical trials.

Kudos to the international team of collaborators on this case:? Raanan Berger ,? Gal Dinstag ,? Omer Tirosh ,?Eyal Schiff, David Kleiner ,? Kenneth Aldape , Eytan Ruppin ,? Tuvik Beker , and Razelle Kurzrock . Society for Immunotherapy of Cancer (SITC) .